Rethinking treatment for nervous system disorders
Empowering patients to live on their own terms
Who We Are
At its core, Eliem is motivated by the promise of helping people live happier, more fulfilling lives. The Eliem team channels its experience, energy and passion for improving patients’ quality of life by developing life-changing novel therapies for neuronal excitability disorders based on clinically validated mechanisms of action.

Our Approach: Optimizing Treatments for Neuronal Excitability Disorders
Tens of millions of people suffer from central and peripheral nervous system disorders, where an imbalance between excitation and inhibition has disrupted the homeostasis in affected neuronal networks. These disorders include a range of common conditions such as chronic pain, depression, epilepsy and anxiety. Currently available treatments for these conditions often fail to provide adequate control or relief, and they are often poorly tolerated, leaving people unable to live life on their own terms.
Developing improved treatments for patients requires a pragmatic and diligent approach. Equal parts rigorous and agile, the experienced Eliem team strives to make treatments that are more effective, safer and better tolerated than currently available treatments. Leveraging clinically validated mechanisms of action, we are moving steadily and efficiently to develop novel therapeutics for neuronal excitability disorders that deliver enhanced outcomes for patients.
Our Pipeline
Our clinical and preclinical pipeline is focused on neuronal excitability conditions of the central and peripheral nervous system. We are developing ETX-155 for major depressive disorder and focal onset seizures. This compound is designed to dramatically improve on the limitations of existing therapies with the potential to be best-in-class for these conditions with high unmet clinical needs.
Our Experienced Team
The team’s combined expertise in neurological research, clinical development, commercialization and company building are critical for delivering on the promise of bringing innovative therapies to market to provide relief and hope for the millions of patients affected by neurological conditions.


























News
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
By Bob Azelby
More restrictive opioid prescribing guidelines were put in place in a rightful effort to stop a devastating crisis. But this sudden and dramatic change negatively impacted chronic pain patients who were managing their pain through prescription opioids given few other effective options.
Careers
We are always looking to grow our team and believe it takes teamwork, trust and tenacity to deliver on the promise of helping patients live happier, more fulfilling lives. If this sounds like you, please indicate which position you are interested in and contact us at Careers US or Careers UK.
We’d love to connect.
Location: Cambridge, UK
About Eliem:
Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases. Our pipeline has clinical and pre-clinical stage compounds focused on pain, depression, epilepsy and other neurological conditions. The company continues to grow its preclinical pipeline in neurology.
Eliem launched in 2018 and completed its initial public offering in 2021. The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com
About this role:
As our development team expands, we have a new opportunity for a part-time toxicology project manager to manage outsourced toxicology studies within discovery and IND-stage project teams for small-molecules.
Key Responsibilities:
- Work with the project teams and strategic toxicology consultant to develop the toxicology strategy and plan to meet the project requirements
- Oversee outsourced preclinical toxicology studies at multiple external Contract Research Organizations (CRO):
- Select appropriate CRO(s)
- In partnership with others on the development team, design the strategy for assessing non-clinical safety for development candidates, including giving strategic advice on timings
- Design & execute investigative toxicology studies, based upon off & on-target safety profiles of the candidate drugs
- Monitor toxicology studies for appropriate conduct, accuracy and timely execution
- Audit raw data for accuracy, review and finalize reports in partnership with CROs as submission-ready documents for regulatory authorities
- Proactively respond to study issues and resolve problems with CRO study director
- Internal and external communication:
- Prepare verbal and written summaries for internal discussions
- Review and/or author toxicology and/or safety pharmacology sections of various regulatory documents (e.g., pre-IND briefing documents, INDs, IBs etc.) and ensure their regulatory compliance
- May represent company at meetings with regulatory agencies
- Present summary data to project teams and Eliem senior leadership
Key Requirements:
- BSc in toxicology, pharmacology or related field
- Significant experience in toxicology small molecule drug development in Biotech/Pharma industry
- May have worked as a study director for a CRO
- An in-depth understanding of toxicology and/or toxicologic pathology with experience designing and critically evaluating results of exploratory and GLP-compliant toxicology studies
- Proven ability to communicate well within a multifunctional drug development team, with excellent oral and written communication skills
- Excellent interpersonal skills and ability to interact with staff at all levels
We offer our employees competitive salary and benefits, including pension (9% employer contribution), life assurance, income protection and private medical insurance. We provide the opportunity for hybrid home and office working.
To apply please send your CV and a covering letter to CareersUK@eliemtx.com, quoting job reference E23/02
Location: Cambridge, UK
About Eliem:
Eliem Therapeutics is a clinical-stage biotechnology company developing medicines for patients with neurologic diseases. Our pipeline has clinical and pre-clinical stage compounds focused on pain, depression, epilepsy and other neurological conditions. The company continues to grow its preclinical pipeline in neurology.
Eliem launched in 2018 and completed its initial public offering in 2021. The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com
About this role:
As our development team expands, we have a new opportunity for a part-time toxicology project manager to manage outsourced toxicology studies within discovery and IND-stage project teams for small-molecules.
Key Responsibilities:
- Work with the project teams and strategic toxicology consultant to develop the toxicology strategy and plan to meet the project requirements
- Oversee outsourced preclinical toxicology studies at multiple external Contract Research Organizations (CRO):
- Select appropriate CRO(s)
- In partnership with others on the development team, design the strategy for assessing non-clinical safety for development candidates, including giving strategic advice on timings
- Design & execute investigative toxicology studies, based upon off & on-target safety profiles of the candidate drugs
- Monitor toxicology studies for appropriate conduct, accuracy and timely execution
- Audit raw data for accuracy, review and finalize reports in partnership with CROs as submission-ready documents for regulatory authorities
- Proactively respond to study issues and resolve problems with CRO study director
- Internal and external communication:
- Prepare verbal and written summaries for internal discussions
- Review and/or author toxicology and/or safety pharmacology sections of various regulatory documents (e.g., pre-IND briefing documents, INDs, IBs etc.) and ensure their regulatory compliance
- May represent company at meetings with regulatory agencies
- Present summary data to project teams and Eliem senior leadership
Key Requirements:
- BSc in toxicology, pharmacology or related field
- Significant experience in toxicology small molecule drug development in Biotech/Pharma industry
- May have worked as a study director for a CRO
- An in-depth understanding of toxicology and/or toxicologic pathology with experience designing and critically evaluating results of exploratory and GLP-compliant toxicology studies
- Proven ability to communicate well within a multifunctional drug development team, with excellent oral and written communication skills
- Excellent interpersonal skills and ability to interact with staff at all levels
We offer our employees competitive salary and benefits, including pension (9% employer contribution), life assurance, income protection and private medical insurance. We provide the opportunity for hybrid home and office working.
To apply please send your CV and a covering letter to CareersUK@eliemtx.com, quoting job reference E23/02
Contact Us
23515 NE Novelty Hill Road, Suite B221 #125
Redmond, WA 98053
Eliem Therapeutics (UK) Ltd: Reg. 11893311
3rd Floor, 1 Ashley Road
Altrincham, Cheshire WA14 2DT